CSF-1 in inflammatory and arthritic pain development
Details
Publication Year 2018-08-17, Volume 201, Issue #7, Page 2042-2053
Journal Title
Journal of Immunology
Publication Type
Journal Article
Abstract
Pain is one of the most debilitating symptoms in many diseases for which there is inadequate management and understanding. CSF-1, also known as M-CSF, acts via its receptor (CSF-1R, c-Fms) to regulate the development of the monocyte/macrophage lineage and to act locally in tissues to control macrophage numbers and function. It has been implicated in the control of neuropathic pain via a central action on microglia. We report in this study that systemic administration of a neutralizing anti-CSF-1R or CSF-1 mAb inhibits the development of inflammatory pain induced by zymosan, GM-CSF, and TNF in mice. This approach also prevented but did not ameliorate the development of arthritic pain and optimal disease driven by the three stimuli in mice, suggesting that CSF-1 may only be relevant when the driving inflammatory insults in tissues are acute and/or periodic. Systemic CSF-1 administration rapidly induced pain and enhanced the arthritis in an inflamed mouse joint, albeit via a different pathway(s) from that used by systemic GM-CSF and TNF. It is concluded that CSF-1 can function peripherally during the generation of inflammatory pain and hence may be a target for such pain and associated disease, including when the clinically important cytokines, TNF and GM-CSF, are involved. Our findings have ramifications for the selection and design of anti-CSF-1R/CSF-1 trials.
Publisher
ASI
WEHI Research Division(s)
Inflammation
PubMed ID
30120124
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2018-10-11 04:23:18
Last Modified: 2018-10-12 03:43:51
An error has occurred. This application may no longer respond until reloaded. Reload 🗙